MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why SMTI Stock advanced +0.11% Today — RQD Quant Desk Flash
$32.92 +0.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $32.86
Sanara MedTech Inc. (SMTI) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $302.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $32.86 (-0.17%)🧬 Cannibal Buyback (-0.60% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 2.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-0.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SMTI)Realized 20D OHLCV Swing Band: ±4%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY SMTI SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)
Altman Z-Score 3.25 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+14/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-0.60% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$35.07-5.4% Next Q
65
Q2 (-2Q)Grade C+$33.16-1.1% Next Q
62
Q3 (-1Q)Grade C$32.80+0.4% Next Q
60
CurrentGrade D+$32.92-0.2% Hist 90D α
57
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the SMTI Bull Thesis Could Fail
Even with a 57/100 (D+) score, SMTI faces multiple-compression risk if 8.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-0.60% YoY Shares) — any gross margin slip below 90.2% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.51) or 200D SMA ($25.48) invalidates the momentum regime and cuts Target Base ($32.77) toward Bear Floor ($25.56).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SMTI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SMTI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SMTI Stock advanced +0.11% Today — RQD Quant Desk Flash
Sanara MedTech Inc. (SMTI) advanced +0.11% to $32.92, trading at 87% of its 52-week range ($16.05 – $35.52). Stretched risk/reward at 8x P/E (16% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 87% of its 52-week range ($16.05 – $35.52) with RSI-14 at 27.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4% around $32.92 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 92.7% gross margin and $2.2M annual free cash flow.
Live SMTI Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SMTI)
- ✓Walkthrough of SMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +73.35%🛡️ HOLDING TREND SUPPORT
2026-10-30O $32.76H $33.19L $32.66C $32.92VOL 97.2K
RES: $36.29SUP: $31.64SMA50: $34.51SMA200: $25.48
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-5.2%/yr Implied 5Y Growth
vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SMTI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SMTI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SMTI)
Health Care Rank #256 of 1016
⚔️ ZJYL vs SMTI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SMTI vs. ZJYL, INGN, AVR, AGPU)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanara MedTech Inc. (SMTI) ranks #256 by composite RQD confidence (57/100, grade D+) and #518 by equity capitalization ($302.4M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SMTI
ACTIVE
Sanara MedTech Inc. | D+ | 57/100 | 8.1x | 92.7% | 16.3% | +0.11% | $302.4M | Benchmark Subject |
| ZJYL JIN MEDICAL INTERNATIONAL LTD. (Class A) | D | 47/100 | — | 29.2% | — | -2.10% | $294.2M | /zjyl-vs-smti → |
| INGN Inogen Inc | E | 29/100 | 8.5x | 52.2% | -27.0% | +0.14% | $192.7M | /ingn-vs-smti → |
| AVR Anteris Technologies Global Corp. | D- | 36/100 | — | 70.3% | -35.0% | +5.25% | $625.9M | /avr-vs-smti → |
| AGPU Axe Compute Inc. | D- | 37/100 | — | — | -35.0% | -2.01% | $101.7M | /agpu-vs-smti → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000714256In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sanara MedTech Inc. (SMTI) reported GAAP revenue of $103.1M (+19.0% vs. FY2024 revenue of $86.7M , and +58.7% cumulative change since FY2023) , GAAP net income of $37.6M, operating cash flow of $6.8M, and free cash flow of $2.2M (+1041.1% YoY). On the balance sheet, SMTI closed FY2025 with $72.9M in total assets against $46.0M in total debt (Altman Z-Score: 3.25, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $103.1M | $37.6M | $6.8M | $2.2M | $72.9M | $46.0M |
| FY2024 (FY) | 2024-12-31 | $86.7M | $9.7M | -$23.8K | -$229.6K | $88.1M | $30.7M |
| FY2023 (FY) | 2023-12-31 | $65.0M | $4.3M | -$3.2M | -$3.2M | — | — |
3. SMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Sanara MedTech Inc. (NASDAQ: SMTI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.92 (+0.11% 1D, market cap $302.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SMTI ranks #256 in composite RQD confidence.
How does SMTI compare to ZJYL and INGN in the Health Care sector?
Within the Health Care sector (Industrial Specialties), SMTI carries a Roarable D+ (57/100 RQD), trailing P/E of 8.1x, gross margin of 92.7%, and ROIC of 16.3%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $294.2M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SMTI?
Per SMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000714256), Sanara MedTech Inc. generated $103.1M in revenue (+19.0% YoY), $37.6M in net income, and $2.2M in free cash flow against $72.9M in total assets and $46.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SMTI trading relative to its 50-day, 200-day, and 52-week technical levels?
SMTI last traded at $32.92 (+0.11% on volume of 35,140 shares), positioning the stock -4.61% below its 50-day simple moving average ($34.51) and +29.20% above its 200-day simple moving average ($25.48). Across its 52-week range of $16.05 to $35.52, SMTI sits at the 86.6% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±4.0% ($31.60 to $34.24).
SMTI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SMTI stock moving today?
Why SMTI Stock advanced +0.11% Today — RQD Quant Desk Flash. Stretched risk/reward at 8x P/E (16% return on capital) under elevated 10-year interest-rate pressure.